Company profile
Panacos Pharmaceuticals, Inc.
OTC: PANC · Healthcare · Biotechnology
PublicHQ Watertown, Reports USD
#1016 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ —GM —SS 46
v0.1 · 5/100 weight · pillars only
↑ operating margin, listing tenure · ↓ Piotroski F, net margin
Methodology →Revenue TTM
$99.0k
Rev growth YoY (TTM)
-45.9%
Net income (FY)
-$37.5M
Employees
41
as of 2026-08-30
Market cap
$5.4k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$180.0k$180.0k2007
Net income-$37.5M-$37.5M2007
Operating income$39.0M$39.0M2007
Total assets$55.7M$55.7M2007
Liabilities$26.8M$26.8M2007
Equity$28.9M$28.9M2007
Revenue trend
FY2000 – FY2007 · USD
FY00
FY01
FY02
FY03
FY04
FY05
FY06
FY07
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Panacos Pharmaceuticals, Inc.’s revenue?
Panacos Pharmaceuticals, Inc. booked $180.0k in FY2007 revenue, contracting 37% year over year — slower than 78% of Healthcare companies we track, at a -20810.6% net margin.
Peers · Healthcare
NuGen Medical Devices Inc.24DAbpro Holdings, Inc.14DPharmaRoth Labs, Inc.——Appili Therapeutics Inc28DMedMira Inc.31DEden Empire Inc.——Key facts
CEOJohn R. Barr
SectorHealthcare
IndustryBiotechnology
HeadquartersWatertown, null
ExchangeOTC: PANC
Employees41
IPO date2005-03-14
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.